EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseVergleichsstudieOpen Access · CC BY-NC 4.0

Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis

Wei Kang, Bowie P Y Lam, Rinko Tsz Lam Lau, Silvia T H Li, Kangrui Wu, Yue Wei, Yu Yang, Kyung Jin Lee, Caige Huang, Vincent K C Yan, Hei Hang Edmund Yiu, Shing Fung Lee und 6 weitere

Drug Safety · 2026

DOI: 10.1007/s40264-026-01684-4 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Drug Safety, 2026. Verfasst von Wei Kang und 17 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China. Hauptthemen laut MEDLINE: Anticoagulants, Heparin, Low-Molecular-Weight, Neoplasms, Thrombosis. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hong Kong Research Grants Council, General Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer-associated thrombosis is a condition associated with high mortality rates, yet limited evidence exists regarding the safety and effectiveness of low-molecular-weight heparin (LMWH) and direct oral anticoagulants (DOACs), focusing on a fixed follow-up period based on clinical practice guideline recommendations.

Objective

This study aimed to compare the safety and effectiveness of DOACs versus LMWH in patients with cancer-associated thrombosis over a 6-month follow-up period.

Methods

PubMed, Embase, and Cochrane Library databases were systematically searched up to 30 June, 2025. Recurrent venous thromboembolism, major bleeding, and all-cause mortality were pooled using a random-effects meta-analysis.

Results

Seven randomized controlled trials and 28 cohort studies were included in our systematic review. After applying the criteria for a 6-month follow-up period, five randomized controlled trials and 16 cohort studies with 49,824 patients were analyzed in the meta-analysis. In randomized controlled trials, DOACs showed a lower incidence of venous thromboembolism recurrence (relative risk [RR] 0.66, 95% confidence interval [CI] 0.49–0.87) compared with LMWH, with a non-significant increase in major bleeding (RR 1.28, 95% CI 0.87–1.88) and no significant difference in all-cause mortality (RR 1.00, 95% CI 0.86–1.18). Cohort studies demonstrated a lower incidence of venous thromboembolism recurrence (RR 0.69, 95% CI 0.62–0.76) with DOACs, a non-significant reduction in major bleeding (RR 0.85, 95% CI 0.68–1.07), and a lower risk of all-cause mortality (RR 0.47, 95% CI 0.31–0.72).

Conclusions

In patients with cancer-associated thrombosis, DOACs demonstrated a decrease in recurrent venous thromboembolism without increasing the risk of all-cause mortality. A non-significant increase in the risk of major bleeding was recorded in randomized controlled trials, but not in cohort studies. DOACs may provide greater effectiveness for cancer-associated thrombosis compared with LMWH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsHeparin, Low-Molecular-WeightNeoplasmsThrombosisHumansAdministration, OralHemorrhageRandomized Controlled Trials as TopicVenous Thromboembolism

Substanzen

AnticoagulantsHeparin, Low-Molecular-Weight

Autor:innen und Institutionen

  • School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
  • Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
  • Institute of Health Economics and Policy, Tianjin University, Tianjin, China.
  • Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Institute of Clinical Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Radiation Oncology, National University Cancer Institute, National University Hospital, Singapore, Singapore.

Förderung

  • Hong Kong Research Grants Council, General Research Fund

Zitieren

APA

Kang, W., Lam, B. P. Y., Lau, R. T. L., Li, S. T. H., Wu, K., Wei, Y., Yang, Y., Lee, K. J., Huang, C., Yan, V. K. C., Yiu, H. H. E., Lee, S. F., Helali, A. E., Lee, V. H. F., Chan, S. L., Hui, R. Y. M., Lam, K. O., & Chan, E. W. (2026). Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis. Drug Safety. https://doi.org/10.1007/s40264-026-01684-4

Vancouver

Kang W, Lam BPY, Lau RTL, Li STH, Wu K, Wei Y, et al. Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis. Drug Safety. 2026. doi:10.1007/s40264-026-01684-4

BibTeX
@article{Kang2026,
  author = {Kang, Wei and Lam, Bowie P Y and Lau, Rinko Tsz Lam and Li, Silvia T H and Wu, Kangrui and Wei, Yue and Yang, Yu and Lee, Kyung Jin and Huang, Caige and Yan, Vincent K C and Yiu, Hei Hang Edmund and Lee, Shing Fung and Helali, Aya El and Lee, Victor H F and Chan, Stephen L and Hui, Rina Y M and Lam, Ka On and Chan, Esther W},
  title = {Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis},
  journal = {Drug Safety},
  year = {2026},
  doi = {10.1007/s40264-026-01684-4}
}
Kostenlos starten →